Compounds > dup 721
Page last updated: 2024-08-02 10:57:30

dup 721

Description

Cross-References

ID SourceID
PubMed CID9882056
CHEMBL ID6462
SCHEMBL ID4402113
MeSH IDM0154443

Synonyms (9)

Synonym
dup-721
CHEMBL6462
SCHEMBL4402113
AKOS030565897
n-[[(5s)-3-(4-acetylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
(s)-n-((3-(4-acetylphenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
MS-23925
EX-A5431
CS-0226367

Bioassays (21)

Assay IDTitleYearJournalArticle
AID274224Antibacterial activity against Staphylococcus aureus UC-76 SA-12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
ISSN: 0960-894X		Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID206547Effective dose required to inhibit Staphylococcus aureus UC9271 in mice subjected to a lethal systemic infection (when administered orally)1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID205577Antibacterial activity against Staphylococcus epidermidis UC30031UC1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID210051Antibacterial activity against Streptococcus pneumoniae UC99121998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID207646Antibacterial activity against Staphylococcus aureus UC92131998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID698976Antimycobacterial activity against Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51ISSN: 1768-3254Tuberculosis: the drug development pipeline at a glance.
AID68043In vitro minimum inhibitory concentration against Enterococcus faecalis (STCO-19)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
ISSN: 0022-2623		Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group.
AID207263In vitro minimum inhibitory concentration against Staphylococcus aureus (SFCO-1a)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
ISSN: 0022-2623		Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group.
AID274227Antibacterial activity against Enterococcus faecalis MGH-2 EF1-12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
ISSN: 0960-894X		Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID207054In vitro for antibacterial activity against Staphylococcus aureus strain SFCO-1a1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
ISSN: 0022-2623		Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group.
AID274226Antibacterial activity against Streptococcus pyogenes C-2032006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
ISSN: 0960-894X		Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID207311Antibacterial activity against Staphylococcus aureus SFCO-1a cell line.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
ISSN: 0022-2623		Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives.
AID66921Antibacterial activity against Enterococcus faecalis STCO-191992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
ISSN: 0022-2623		Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives.
AID206546Effective dose required to inhibit Staphylococcus aureus UC9213 in mice subjected to a lethal systemic infection (when administered orally)1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID67086Antibacterial activity against Enterococcus faecalis UC92171998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID1151705Antibacterial activity against Staphylococcus aureus2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804		New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
AID41245Antibacterial activity against Bacteroides fragilis UC121991998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID274223Antibacterial activity against Escherichia coli by transcription and translation assay2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
ISSN: 0960-894X		Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID67419In vitro for antibacterial activity against Enterococcus faecalis strain STCO-191990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
ISSN: 0022-2623		Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group.
AID207645Antibacterial activity against Staphylococcus aureus UC126731998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
ISSN: 0960-894X		Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID274225Antibacterial activity against Streptococcus pneumoniae SVI SP-32006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
ISSN: 0960-894X		Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's3 (42.86)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
isoniazid
1
carbohydrazideantitubercular agent;
drug allergen		2012201212.0low000010
gatifloxacin
1
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor		2012201212.0low000010
vancomycin
3
glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite		1989201423.7medium011010
cephalexin
1
beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug1989198935.0low010000
dup 105
2
1990201223.0high001010
moxifloxacin
1
aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug2012201212.0low000010
azd2563
1
2012201212.0low000010
linezolid
4
acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor		1998201416.5medium001120
pa 824
1
2012201212.0low000010
u 100480
1
2012201212.0low000010
sq 109
1
2012201212.0low000010
bedaquiline
1
aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor		2012201212.0low000010
opc-67683
1
piperidines2012201212.0low000010
gentamicin sulfate
1
1989198935.0low010000
tedizolid
1
carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor		2014201410.0low000010
tedizolid phosphate
1
carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles		antimicrobial agent;
prodrug;
protein synthesis inhibitor		2014201410.0low000010
btz 043
1
2012201212.0low000010
rifampin
1
cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor		2012201212.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Bacterial Disease0
1
1998199826.0medium001000
Bacterial Infections0
1
1998199826.0medium001000
Bacterial Infections, Gram-Positive0
1
2014201410.0medium000010
Blood Poisoning0
1
2014201410.0medium000010
Gram-Positive Bacterial Infections0
1
2014201410.0medium000010
Koch's Disease0
1
2012201212.0medium000010
Sepsis0
1
2014201410.0medium000010
Tuberculosis0
1
2012201212.0medium000010

Safety/Toxicity (1)

ArticleYear
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11		2014